Marshall Wace, LLP Catalyst Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

$90.8 Billion
Q3 2025

A detailed history of Marshall Wace, LLP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 24,103 shares of CPRX stock, worth $558,707. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,103

Previous 140,823 82.88%

Holding current value

$558,707

Previous $3.06 Million 84.48%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$19.13 - $22.22 $2.23 Million - $2.59 Million	-116,720 Reduced 82.88%	24,103 $474,000
Q2 2025 Aug 13, 2025	BUY	$21.4 - $26.31 $3.01 Million - $3.71 Million	140,823 New	140,823 $3.06 Million
Q4 2024 Feb 13, 2025	SELL	$19.73 - $23.93 $12 Million - $14.5 Million	-607,297 Reduced 70.54%	253,637 $5.29 Million
Q3 2024 Nov 14, 2024	SELL	$15.19 - $21.35 $5.45 Million - $7.66 Million	-358,603 Reduced 29.4%	860,934 $17.1 Million
Q2 2024 Aug 14, 2024	SELL	$14.68 - $16.92 $6.82 Million - $7.86 Million	-464,414 Reduced 27.58%	1,219,537 $18.9 Million

Q1 2024 May 15, 2024	BUY	$13.18 - $17.11 $22.2 Million - $28.8 Million	1,683,951 New	1,683,951 $26.8 Million
Q3 2023 Nov 14, 2023	SELL	$11.69 - $15.02 $1.4 Million - $1.8 Million	-120,012 Reduced 61.86%	73,991 $864,000
Q2 2023 Aug 14, 2023	BUY	$11.5 - $18.08 $2.23 Million - $3.51 Million	194,003 New	194,003 $2.61 Million
Q1 2022 May 16, 2022	SELL	$5.31 - $8.31 $1.06 Million - $1.66 Million	-200,308 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.21 - $7.45 $1.04 Million - $1.49 Million	200,308 New	200,308 $1.36 Million
Q2 2021 Aug 13, 2021	SELL	$4.29 - $6.05 $443,294 - $625,158	-103,332 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$3.45 - $4.69 $132,707 - $180,405	-38,466 Reduced 27.13%	103,332 $476,000
Q4 2020 Feb 16, 2021	SELL	$2.97 - $3.83 $460,890 - $594,347	-155,182 Reduced 52.25%	141,798 $474,000
Q3 2020 Nov 16, 2020	SELL	$2.97 - $5.08 $96,376 - $164,846	-32,450 Reduced 9.85%	296,980 $882,000
Q2 2020 Aug 13, 2020	SELL	$3.48 - $5.05 $2.7 Million - $3.92 Million	-775,996 Reduced 70.2%	329,430 $1.52 Million
Q1 2020 May 15, 2020	SELL	$2.61 - $5.21 $1.21 Million - $2.41 Million	-462,138 Reduced 29.48%	1,105,426 $4.26 Million
Q4 2019 Feb 14, 2020	BUY	$3.67 - $5.7 $5.75 Million - $8.94 Million	1,567,564 New	1,567,564 $5.88 Million

Others Institutions Holding CPRX

# of Institutions

394

Shares Held

106M

Call Options Held

164K

Put Options Held

439K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.38B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Catalyst Pharmaceuticals, Inc. Transaction History